Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news

Show

From To
Janssen Announces New Group Targeting Unmet Global Health Needs

Janssen GPH will be responsible for clinical and product development and creating and implementing innovative new access strategies for a growing portfolio of pharmaceuticals, diagnostics, and services for diseases significantly impacting resource-limited countries and emerging markets, and includes bedaquiline for drug-resistant TB, long-lasting injectable rilpivirine for HIV prevention and the dapivirin ring for HIV prevention.

Published
22 January 2014
From
Janssen press release
USAID, Population Council agreement for non-antiretroviral microbicide quest looks to expand prevention toolbox

An agreement between the United States Agency for International Development and the Population Council announced Monday for the development of a non-antiretroviral-based compound to block HIV and other sexually transmitted infections could yield a low-risk, easy access product for women in low resource settings in as few as a dozen years, if a promising new compound performs as hoped. That is a big if - the field of microbicide research has seen a roller coaster of raised expectations and dashed hopes over the last decades.

Published
11 January 2014
From
Science Speaks
AAPS showcases vaginal ring with tenofovir + contraceptive, gel suitable for vaginal and rectal use

A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.

Published
21 November 2013
From
HIVandHepatitis.com
Novel microbicide gel for vagina and rectum shows potential for HIV prevention

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus. The DuoGel will deliver ImQuest's antiretroviral compound IQP-0528.

Published
15 November 2013
From
Eurekalert Inf Dis
HIV Microbicides Require Safety, Efficacy, Good Marketing

Designing a successful topical microbicide against HIV must balance efficacy and toxicity. Microbicides are intended to cut down the risk for transmission of HIV, and they may give a measure of control to people whose partners do not use condoms.

Published
30 October 2013
From
Medscape (requires free registration)
IPM Receives Two Awards from USAID to Advance HIV Prevention Technologies for Women

The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID). Both awards aim to advance new HIV prevention tools for women and to help ensure their availability in developing countries where the epidemic has hit hardest.

Published
22 October 2013
From
International Partnership for Microbicides
Researchers and advocates discuss the microbicides pipeline in Europe

The first day of the 14th European AIDS Conference, which opened yesterday in Brussels, featured a satellite symposium on development of HIV microbicides, broadly defined to include a

Published
17 October 2013
By
Liz Highleyman
Microbicide ring study shows users are reassured about discomfort but develop new worries about safety

A safety and acceptability study of a vaginal ring containing the antiretroviral drugs dapivirine (TMC120) and/or maraviroc (Celsentri, Selzentry) shows that women using the ring generally found

Published
03 October 2013
By
Gus Cairns
Researchers launch first-ever phase II safety study of rectal microbicide to prevent HIV

Taking an important step toward the development of a product to prevent HIV infections associated with unprotected anal sex, researchers today announced the launch of a global Phase II clinical trial of a potential rectal microbicide. The trial, led by the US National Institutes of Health-funded Microbicide Trials Network, is testing the rectal use of a reduced glycerin gel formulation of the antiretroviral drug tenofovir.

Published
03 October 2013
From
Eurekalert Inf Dis
Tenofovir vaginal ring protects monkeys on Depo-Provera against HIV-like virus

An intravaginal ring containing tenofovir protected all but one macaque monkey given hormonal contraceptives and repeatedly exposed to a hybrid human/simian virus similar to HIV, according to

Published
30 September 2013
By
Liz Highleyman

Filter by country